BACKGROUND: Resection of gliomas located in eloquent brain areas remains a neurosurgical challenge. The reported incidence of transient or permanent neurological deficits after microsurgery in eloquent brain ranges 20%-100%, or 0%-47% among contemporary neurosurgical series. The aim of this study was to assess the feasibility of stereotactic brachytherapy (SBT) as a local treatment alternative to microsurgical resection for patients with gliomas in highly eloquent areas, located in the central sulcus region (CSR). METHOD: Between 1997 and 2010, 60 patients with World Health Organization (WHO) grades II and III gliomas located in the CSR were treated with SBT (iodine-125 seeds; cumulative therapeutic dose, 50-65 Gy). Following SBT, WHO grade III glioma patients additionally received percutaneous radiotherapy (median boost dose, 25.2 Gy). We evaluated procedure-related complications, clinical outcome, and progression-free survival. RESULTS: Procedure-related mortality was zero. Within 30 days of SBT, 3 patients (5%) had transient neurological deficits, and 8 patients (13%) had temporarily increased seizure activity. One patient (1.6%) deteriorated permanently. Space-occupying cysts (6 patients) and radiation necrosis (1 patient) developed after a median of 38 months and required surgical intervention. Seizure activity, rated 12 months following SBT, decreased in 82% of patients (Engel classes I-III). Median progression-free survivals were 62.2 ± 19.7 months (grade II gliomas) and 26.1 ± 17.9 months (grade III gliomas). CONCLUSIONS: Compared with microsurgical resection, SBT harbors a low risk of procedural complications, is minimally invasive, and seems to be an effective local treatment option for patients with inoperable, eloquent WHO grade II and III gliomas in the CSR. However, the value of SBT for treating gliomas still needs to be determined in prospective, randomized studies.
BACKGROUND: Resection of gliomas located in eloquent brain areas remains a neurosurgical challenge. The reported incidence of transient or permanent neurological deficits after microsurgery in eloquent brain ranges 20%-100%, or 0%-47% among contemporary neurosurgical series. The aim of this study was to assess the feasibility of stereotactic brachytherapy (SBT) as a local treatment alternative to microsurgical resection for patients with gliomas in highly eloquent areas, located in the central sulcus region (CSR). METHOD: Between 1997 and 2010, 60 patients with World Health Organization (WHO) grades II and III gliomas located in the CSR were treated with SBT (iodine-125 seeds; cumulative therapeutic dose, 50-65 Gy). Following SBT, WHO grade III gliomapatients additionally received percutaneous radiotherapy (median boost dose, 25.2 Gy). We evaluated procedure-related complications, clinical outcome, and progression-free survival. RESULTS: Procedure-related mortality was zero. Within 30 days of SBT, 3 patients (5%) had transient neurological deficits, and 8 patients (13%) had temporarily increased seizure activity. One patient (1.6%) deteriorated permanently. Space-occupying cysts (6 patients) and radiation necrosis (1 patient) developed after a median of 38 months and required surgical intervention. Seizure activity, rated 12 months following SBT, decreased in 82% of patients (Engel classes I-III). Median progression-free survivals were 62.2 ± 19.7 months (grade II gliomas) and 26.1 ± 17.9 months (grade III gliomas). CONCLUSIONS: Compared with microsurgical resection, SBT harbors a low risk of procedural complications, is minimally invasive, and seems to be an effective local treatment option for patients with inoperable, eloquent WHO grade II and III gliomas in the CSR. However, the value of SBT for treating gliomas still needs to be determined in prospective, randomized studies.
Entities:
Keywords:
central sulcus region; eloquent gliomas; stereotactic iodine-125 brachytherapy, SBT
Authors: Andrea Talacchi; Sergio Turazzi; Francesca Locatelli; Francesco Sala; Alberto Beltramello; Franco Alessandrini; Paolo Manganotti; Paola Lanteri; Roberta Gambin; Mario Ganau; Vincenzo Tramontano; Barbara Santini; Massimo Gerosa Journal: J Neurooncol Date: 2010-05-14 Impact factor: 4.130
Authors: Christian Hartmann; Bettina Hentschel; Wolfgang Wick; David Capper; Jörg Felsberg; Matthias Simon; Manfred Westphal; Gabriele Schackert; Richard Meyermann; Torsten Pietsch; Guido Reifenberger; Michael Weller; Markus Loeffler; Andreas von Deimling Journal: Acta Neuropathol Date: 2010-11-19 Impact factor: 17.088
Authors: R Soffietti; B G Baumert; L Bello; A Von Deimling; H Duffau; M Frénay; W Grisold; R Grant; F Graus; K Hoang-Xuan; M Klein; B Melin; J Rees; T Siegal; A Smits; R Stupp; W Wick Journal: Eur J Neurol Date: 2010-09 Impact factor: 6.089
Authors: José M González-Darder; Pablo González-López; Fernando Talamantes; Vicent Quilis; Victoria Cortés; Guillermo García-March; Pedro Roldán Journal: Neurosurg Focus Date: 2010-02 Impact factor: 4.047
Authors: Edward F Chang; Aaron Clark; Justin S Smith; Mei-Yin Polley; Susan M Chang; Nicholas M Barbaro; Andrew T Parsa; Michael W McDermott; Mitchel S Berger Journal: J Neurosurg Date: 2010-07-16 Impact factor: 5.115
Authors: Philipp Kickingereder; Christina Hamisch; Bogdana Suchorska; Norbert Galldiks; Veerle Visser-Vandewalle; Roland Goldbrunner; Martin Kocher; Harald Treuer; Juergen Voges; Maximilian I Ruge Journal: J Neurooncol Date: 2014-08-24 Impact factor: 4.130
Authors: Dilini S Pinnaduwage; Shiv P Srivastava; Xiangsheng Yan; Shyam Jani; David G Brachman; Stephen P Sorensen Journal: Technol Cancer Res Treat Date: 2022 Jan-Dec
Authors: Faycal El Majdoub; Clemens Neudorfer; Tobias Blau; Martin Hellmich; Christian Bührle; Martina Deckert; Volker Sturm; Mohammad Maarouf Journal: Strahlenther Onkol Date: 2015-08-26 Impact factor: 3.621
Authors: B Suchorska; C Hamisch; H Treuer; K Mahnkopf; R E Lehrke; M Kocher; M I Ruge; J Voges Journal: J Neurooncol Date: 2016-07-15 Impact factor: 4.130